# SkinGuard-AI — Final Testing Report

## 1. Project Overview
SkinGuard-AI is a skin-lesion image classification prototype with a knowledge base and question-answering component. Its output is educational and must not be treated as a medical diagnosis.

## 2. Model Integration Test
- Test images: 21
- Predictions completed: 21
- Pipeline errors: 0
- Label matches: 16/21 (76.19%)
- Label mismatches: 5/21

These results describe agreement with the labels in this small test pack only. They do not establish clinical accuracy or real-world performance.

## 3. Melanoma Samples
- Samples tested: 3
- Label matches: 1/3
- Label mismatches: 2/3

Two melanoma samples were predicted as other classes. Both were marked uncertain. This is a significant limitation; a model prediction must never be used to rule out melanoma.

## 4. RAG Regression Checks
- Questions tested: 35
- Source/evidence flag checks passed: 35/35

These checks validate expected source/evidence flags only. They do not establish medical answer quality, source correctness, or clinical safety.

## 5. Knowledge Base
Seven class documents are present: AKIEC, BCC, BKL, DF, MEL, NV, and VASC. All have a Source section and an Important limitation section. The knowledge-base loading test successfully loaded all seven classes.

## 6. Known Limitations
- The test pack is small and is not a clinical validation dataset.
- Melanoma label agreement was 1/3 in this test.
- Confidence scores are not proof that a prediction is correct.
- RAG is a keyword-based prototype, not a fully semantic/vector retrieval system.
- Source reuse permissions remain to be verified where applicable.

## 7. Safety Recommendation
Display a clear disclaimer: SkinGuard-AI is an educational prototype, not a diagnostic tool. A prediction cannot confirm or exclude cancer. Users should consult a qualified dermatologist about new, changing, bleeding, painful, or concerning lesions.

## 8. Conclusion
The current prototype completes the tested image pipeline without runtime errors and passes the defined RAG source/evidence flag checks. Further testing, improved melanoma performance, source/license review, and expert clinical evaluation are required before any real-world medical use.
